Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.57 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31556450 | 1.00 | NOTUM (0.57) | NOTUMACLYCA12CA1CA2 | |
| SCHEMBL3343549 | 0.87 | CA12 (0.52) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL19518886 | 0.85 | NOTUM (0.55) | NOTUMACLYCA12CA1CA2 | |
| SCHEMBL16903501 | 0.85 | NOTUM (0.55) | NOTUMACLYCA12CA1CA2 | |
| Methyl 3,5-Dibromobenzoate SCHEMBL2408987 | 0.81 | NOTUM (0.67) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL184614 | 0.81 | NOTUM (0.67) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL26334428 | 0.81 | NOTUM (0.51) | NOTUMACLYCA12CA1CA2 | |
| SCHEMBL3509317 | 0.81 | LCK (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL20791126 | 0.81 | CNR2 (0.47) | CA12CA1CA2CA9CA14 | |
| SCHEMBL3898102 | 0.81 | KDM4E (0.46) | NOTUMCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068354-A1 | SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-03 | — | — | WO | disclosed |
| CN-117043162-A | TYK2 selective inhibitors and uses thereof | 迈巴制药(南京)有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-2262766-B1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| EP-2262766-B1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| WO-2009110985-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-7476764-B2 | Phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476764-B2 | Phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476764-B2 | Phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-13 | — | — | US | disclosed |
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-08 | — | — | US | disclosed |
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-08 | — | — | US | disclosed |
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-08 | — | — | US | disclosed |
| US-5849775-A | Substituted benzoylguanidines process for their preparation, their use as a medicament or diagnostic, and pharmaceutical containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-15 | — | — | US | disclosed |
| US-5693672-A | 3,4,5-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | disclosed |
| US-5679712-A | ANTIARRHYTHMIA AGENTS, TREATMENT OF CARDIOVASCULAR, NERVOUS SYSTEM DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BACE1, APP, BACE2 | NOTUM 506/4885ACLY 1256/4885CA12 3717/4885 |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | IL1B, ADORA2B, AVPR1B | NOTUM 3040/4885ACLY 113/4885CA12 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.